Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. [electronic resource]
Producer: 20030731Description: 971-3 p. digitalISSN:- 0268-3369
- Adult
- Amsacrine -- administration & dosage
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Benzamides
- Betamethasone -- administration & dosage
- Biomarkers, Tumor -- genetics
- Combined Modality Therapy
- Cyclophosphamide -- administration & dosage
- Cytarabine -- administration & dosage
- Daunorubicin -- administration & dosage
- Drug Resistance, Neoplasm
- Enzyme Inhibitors -- therapeutic use
- Etoposide -- administration & dosage
- Female
- Fusion Proteins, bcr-abl -- genetics
- Graft vs Host Disease -- drug therapy
- Humans
- Imatinib Mesylate
- Immunosuppressive Agents -- therapeutic use
- Mitoxantrone -- administration & dosage
- Neoplasm, Residual
- Peripheral Blood Stem Cell Transplantation
- Piperazines -- therapeutic use
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Pyrimidines -- therapeutic use
- Remission Induction
- Reverse Transcriptase Polymerase Chain Reaction
- Transplantation, Homologous
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.